Alivus Life Sciences Limited will host a plant visit for institutional investors on June 29, 2026, at its manufacturing facility in Ankleshwar, Gujarat. The meeting is intended to provide investors with an on-site overview of the company's operations and will be conducted in-person. The event may include both group and one-on-one interactions, depending on the requirements of the attendees.

The disclosure was made to the stock exchanges in compliance with Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company noted that the schedule and mode of the meeting are subject to change due to unforeseen circumstances on the part of the investors or the company.

The table below outlines the details of the scheduled plant visit:

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, operates through its corporate office in Mumbai and registered office in Solapur. The company's compliance officer, Rudalf Corriea, signed the disclosure on June 23, 2026.

Nirma Limited has confirmed that it did not create any encumbrance on the shares of Alivus Life Sciences held by it during the financial year 2025-26. The disclosure, addressed to the stock exchanges, states that the promoter group has not pledged or otherwise encumbered its shareholding, either directly or indirectly, throughout the specified period.

The filing was made to comply with Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011. This regulation requires promoters to disclose any encumbrance on shares held by them to ensure transparency for shareholders and the market.

The communication was signed by Paresh Sheth, Company Secretary of Nirma Limited, on April 7, 2026. Copies of the disclosure were also sent to the members of the Audit Committee of Alivus Life Sciences Limited. The company was formerly known as Glenmark Life Sciences Limited.